Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Two William Blair Clients Named Middle-Market Deals of the Year by Mergers & Acquisitions

    Congratulations to William Blair clients Commodity & Ingredient Hedging LLC, a portfolio company of Falfurrias Capital Partners, and Stout, a portfolio company of Audax Private Equity, for being recognized on Mergers & Acquisitions’ list of 2026 Mid-Market Deals of the Year.

    Read more

  • College Was Awesome. Now What?

    College graduation marks the start of a career with new responsibilities and decisions. It can be an exciting time but filled with uncertainty.

    Read more

  • Thibaut Has Been Acquired by Quad-C

    William Blair acted as financial advisor to Thibaut, a portfolio company of Norwest Equity Partners, in connection with its sale to Quad-C Management.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures